Clinical trial · Observational
Nutritional Supplement Based on Myo-inositol-D-chiro-inositoln in Long-term Survivors of Lymphoma
Nutritional Supplement Based on Myo-inositol-D-chiro-inositol: Effectiveness on the Reproductive System Functionality in Long-term Survivors of Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The progressive improvement of lymphoma treatment has led to an important prolongation of patient survival and life expectancy. Therefore, the principal International scientific societies of oncology, recommend Long-term Survivors of Lymphoma to join fertility programs. Specifically, fertile age patients should be assisted by a multi-disciplinary team including specialists dedicated to fertility preservation in oncology, in order to support the completion of the reproductive project. In general population, the use of Inositol was spready considered an effectives choice to contrast ovarian dysfunction with consequently improvement of reproductive outcomes, so it may represent an adjuvant strategy for this purpose. Therefore, the investigators conducted a pilot study to evaluate the potentialities of this nutritional supplement with the aim to optimize the reproductive function in Long-term Survivors of Lymphoma. Despite the limited number of cases and short observational time, this pilot investigation could represent a potential cornerstone for further insights, discussions, and applications
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fertility Disorders | — | UNRESOLVED | — |
| Lymphoma, Hodgkin | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Menstrual Irregularity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Myo-Inositol and D-Chiro-Inositol (MIC) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- cHL (85%) and DLBCL (15%)
- description
- Patients enrolled in this study are cHL (85%) and DLBCL (15%) long-term survivors, treated mainly with ABVD+ radiotherapy (not under diaphragmatic and pelvic irradiation), without relapse (during quinquennial follow-up) who are followed at the clinic dedicated to fertility in oncology of our Department, which is a regional referral center for this purpose. Therefore, the investigators conducted a prospective observational controlled study on two groups: the first one (A group) underwent oral supplementation with MIC for 12 months; the second group (B group) underwent follow-up without any nutritional supplement for 12 months
- interventionNames
- Drug: Myo-Inositol and D-Chiro-Inositol (MIC)
Primary outcomes (1)
- measure
- Number of Lymphoma long-term survivors treated with myo-inositol-D-chiro-inositol: evaluation of the results on the reproduction apparatus
- timeFrame
- 12 months
- description
- The investigatirs conducted a prospective observational controlled study on two groups: the first one (A group) underwent oral supplementation with myo-inositol-D-chiro-inositol for 12 months; the second group (B group) underwent follow-up without any nutritional supplement for 12 months.Moreover, the investigators reported for each patient the menstrual frequency ( oligomenorrhea \<25 days , normal flow 25-36 days , polymenorrhea \>36 days), the duration of the cycle (short \< 3 days, normal: 3-7 days , long \>7 days), the amount of the menstrual cycle (poor \<30 ml, normal 30-80 ml, \>80 ml abundant) and dysmenorrhea and dyspareunia (visual analogue scale VAS pain scale = 1 -10).In addition, results of blood tests and clinical data about menstrual regularity and dysmenorrhea, were reported on the same database.In addition, results of blood tests and clinical data about menstrual regularity and dysmenorrhea, were reported on the same database.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 44 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with Classical Hodgkin lymphoma (cHL) and Diffuse Large B-cell lymphoma (DLBCL) long survival Exclusion Criteria:
References
Publications (0)
Data not yet available